Going further for childhood cancer
We’re setting our sights on creating more effective, targeted medicines for children and young people with cancer, bridging the gap between the lab and patients.
Children's Cancer Therapeutics Consortium
Founding partners
How we can help
Rising to the challenge of cancers affecting children and young people will require a fundamental change in the way cancer drugs for this group are discovered, developed and brought to market. That's why we're providing funding and drug discovery lab support to de-risk early stage therapeutic projects and increase their chances of being picked up by industry and impact investors.
Starting with an initial investment of £28m (USD $36m) in resource and funding, we will drive change through collaborative research, partnerships and funding. Join our mission and work with us to help make a difference for children and young people with cancer.
Industry-leading expertise
Bringing together leading experts in research, translational science, drug discovery and development.
Extensive resources
Offering access to world-class drug discovery and development laboratories to accelerate and de-risk promising research.
Transformational models
Raising and managing the financing needed to progress research aimed at developing new treatments for children and young people affected by cancer.
Dynamic collaboration
Convening international experts and complementary skillsets – bringing like-minded organisations and people together to provide resources and expertise to propel innovations along the drug development pathway.
About us: our founding partners
Cancer Research Horizons
Cancer Research Horizons is the innovation engine of Cancer Research UK – the world's largest charitable funder of cancer research. It takes cutting-edge innovations from the lab to the patient, translating them into effective treatments and diagnostics.
LifeArc
LifeArc is a self-funded, not-for-profit medical research organisation and charity. LifeArc provides funding, research and expert knowledge to help take science ideas out of the lab and turn them into life-changing medical breakthroughs for patients.
C-Further will bring together the brightest minds in cancer research to bolster translation of discovery research, drive clinical progress and meaningfully improve the lives of children and young people with cancer.
Iain Foulkes
CEO, Cancer Research Horizons | Executive Director of Research and Innovation, Cancer Research UK
For researchers
Do you have a validated target or an early-stage therapeutic asset with potential in a cancer affecting children and young people?
For partners
Do you share our vision for transformative treatments specifically targeting the drivers of childhood cancers?
Rising to the challenge of childhood cancer requires a fundamental change in the way children’s and young people’s cancer drugs are discovered, developed and brought to market. C-Further is committed to driving that change.
David Jenkinson
Head of Childhood Cancer Translational Challenge, LifeArc
News and events
We are creating a consortium united in the unwavering belief that we can challenge conventional approaches and accelerate translation of promising ideas into new therapies for children and young people affected by cancer.
Stay up to date on our latest news, events and research.
Researcher webinar: Exploring children's and young people's cancers - Therapeutic discovery
Hear from researchers working to develop more effective and targeted treatments for children and young people affected by cancer.
A vision of the future with C-Further
David Jenkinson, Head of Childhood Cancer at LifeArc discusses C-Further's vision to drive impact for patients.
Researcher webinar
Watch our webinar recording to find out how to apply for support to translate your discoveries. This webinar covers everything you need to know to answer our call for projects and submit your expression of interest.
Failing the most vulnerable
Sam Daems explains why traditional drug discovery models have failed to improve paediatric cancer care and what we can do about it.